The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Tamsulosin for the Treatment of Voiding Dysfunction in Women – A Review


Affiliations
1 Aristo Pharmaceuticals Ltd, 23-A Shah Industrial Estate, Veera Desai Road, Andheri (West), Mumbai, India
     

   Subscribe/Renew Journal


Lower urinary tract symptoms (LUTS) have high prevalence worldwide in the aging population including both, men and women and with the advancing age, the incidence of LUTS continues to increase. Interference of the symptoms with the daily activities has a negative impact on the quality of life of many individuals. Apart from watchful waiting and surgery, medical therapies have shown to provide significant control of LUTS. α1- adrenergic receptor blockers are used as first-line therapy for men to alleviate Benign Prostatic Hyperplasia (BPH) induced urinary symptoms. Similar underlying etiology of LUTS in men and women proposes the utility of α1-adrenergic receptor blockers for female lower urinary tract symptoms (FLUTS). Tamsulosin, the highly uroselective α1-adrenergic receptor blocker, has steadily borne positive results in symptomatic management of FLUTS. Improvement in quality of life has been a vital criteria in the assessment of the efficacy of Tamsulosin. All the reviewed studies substantiate the safety and tolerability of Tamsulosin. Numerous clinical trials of Tamsulosin in women suggest the suitability of Tamsulosin as an appropriate therapeutic option for management of female LUTS.

Keywords

Tamsulosin, Luts/ Fluts, α1-adrenergic Receptors, Bladder, Urethra.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P.

  • Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology 2006; 50(6):1306-15

  • Meyer LE, Brown JN. Tamsulosin for voiding dysfunction in women. International urology and nephrology 2012;44(6):1649-56.

  • Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. American journal of obstetrics and gynecology. 2002;187(1):116-26.

  • Goodwin J.(2012) Incontinence Affects Young Childless Women, Too. HealthDay®https://consumer.healthday.com/senior-citizen-information-31/age-health-news-7/incontinenceaffects-young-childless-women-too-666623.html Accessed 25 August 2016.

  • Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP, Wein AJ. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU international. 2009;104(3):352-60.

  • Booth AM. Physiology of the urinary bladder and urethra. Annals of internal medicine.1980. 92(2_Part_2):312-5.

  • Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. American journal of obstetrics and gynecology. 2002;187(1):116-26.

  • Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, WeinAJ.How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study. BJU international.2001;87(9):760-6.

  • Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology. 2006;50(6):1306-15.

  • Wagg AS, Cardozo L, Chapple C, De Ridder D, Kelleher C, Kirby M, Milsom I, Vierhout M. Overactive bladder syndrome in older people. BJU international .2007;99(3):502-9.

  • Patel R, Nitti VW.Bladder outlet obstruction in women: prevalence, recognition, and management. Current urology reports.2001;2(5):379-87.

  • Andersson, K. E., &Gratzke, C. Pharmacology of the lower urinary tract. Textbook of the neurogenic bladder 2008; 2:81-100.

  • Schwinn DA. Novel role for α1‐adrenergic receptor subtypes in lower urinary tract symptoms. BJU international.2000; 86(s2):11-22.

  • Price D. Potential mechanisms of action of superselective α1adrenoceptor antagonists.European urology .2001;40(Suppl. 4):5-11.

  • Urinary incontinence: The management of urinary incontinence in women; NICE Clinical Guideline (2013), Royal College of Obstetricians and Gynecologists. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/themanagementof-urinary-incontinence-in-women-nice-clinicalguideline-171/ Accessed 6 May 2016

  • Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non‐drug active therapies for non‐neurogenic overactive bladder syndrome in adults.Cochrane Database of Systematic Reviews.2012;Issue 12. Art. No.: CD003193.

  • Mirabegron (Betmiga): risk of severe hypertension and associated cerebrovascular and cardiac events; Drug Safety Update, Medicines and Healthcare products Regulatory Agency (MHRA). (2015). https://www.gov.uk/drug-safetyupdate/mirabegron-betmiga-risk-of-severe-hypertensionand-associated-cerebrovascular-and-cardiac-events Accessed 31 May 2016

  • Boyd K, Hilas O. α-Adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women. Annals of Pharmacotherapy.2014;48(6):711-22.

  • Michel MC, Grübbel B, Taguchi K, Verfürth F, Otto T, Kröpfl D. Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned α1‐adrenoceptor subtypes and in human prostate. Journal of autonomic pharmacology. 1996;16(1):21-8.

  • Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant α 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. European Journal of Pharmacology: Molecular Pharmacology.1995;288(2):201-7.

  • Taguchi K, Schäfers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. British journal of clinical pharmacology.1998;45(1):49-55.

  • Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia.Reviews in urology. 2007;9(4):181.

  • Reitz A, Haferkamp A, Kyburz T, Knapp PA, Wefer B, Schurch B. The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. European urology. 2004;46(2):235-40.

  • Pummangura N, Kochakarn W. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian Journal of Surgery .2007;30(2):131-7.

  • Lee KS, Han DH, Lee YS, Choo MS, Yoo TK, Park HJ, Yoon H, Jeong H, Lee SJ, Kim H, Park WH. Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study. Journal of Korean medical science .2010; 25(1):117-22.

  • Kakizaki H, Ameda K, Kobayashi S, Tanaka H, Shibata T, Koyanagi T. Urodynamic effects of α1‐blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. International journal of urology. 2003;10(11):576-81.

  • Lee S, Lee W, Lee S, Kim H, Park C. The effect oftamsulosin in female patients with lower urinary tractsymptoms and predictive factors for therapeutic outcome:multicenter, prospective study. IntUrogynecol J.2011;22(suppl 3):S1781.

  • Pischedda A, Pirozzi Farina F, Madonia M, Cimino S, MorgiaG.Use of α1-blockers in female functional bladder neck obstruction. Urologia internationalis.2005;74(3):256-61.

  • Ryu S, Kim S, Hwang E, Im C, Oh K, Jung S et al.The role of alpha 1(A) adrenoreceptor antagonist tamsulosinfor the treatment of patients with lower urinary tractsymptoms in women: the effect of nocturia and sleep quality. Urology.2010; 76(suppl 3A):S61.

  • Hajebrahimi S, Asrbadr YA, Azaripour A, Sadeghi-Bazargani H. Effect of tamsulosin versus prazosin on clinical and urodynamic parameters in women with voiding difficulty: a randomized clinical trial. International journal of general medicine. 2011;4:35.

  • Costantini E, Lazzeri M, Bini V, Zucchi A, Fioretti F, Frumenzio E, Porena M. Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women. Urologia internationalis.2009;83(3):311-5.

  • Kim SO, Hwang EC, Oh KJ, Kwon D, Park K, Ryu SB. Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s. International urogynecology journal.2011;22(10):1287-91.

  • Neĭmark, AI, Razdorskaia, MV, Kondrat’eva, I., &Muzalevskaia, NI . [Correction of urodynamic disorders in women with obstructive urination]. Urologiia (Moscow, Russia: 1999), 2012;(5), 34-37.


Abstract Views: 271

PDF Views: 0




  • Tamsulosin for the Treatment of Voiding Dysfunction in Women – A Review

Abstract Views: 271  |  PDF Views: 0

Authors

Manish Maladkar
Aristo Pharmaceuticals Ltd, 23-A Shah Industrial Estate, Veera Desai Road, Andheri (West), Mumbai, India
Chitra Tekchandani
Aristo Pharmaceuticals Ltd, 23-A Shah Industrial Estate, Veera Desai Road, Andheri (West), Mumbai, India
Nehali Save
Aristo Pharmaceuticals Ltd, 23-A Shah Industrial Estate, Veera Desai Road, Andheri (West), Mumbai, India

Abstract


Lower urinary tract symptoms (LUTS) have high prevalence worldwide in the aging population including both, men and women and with the advancing age, the incidence of LUTS continues to increase. Interference of the symptoms with the daily activities has a negative impact on the quality of life of many individuals. Apart from watchful waiting and surgery, medical therapies have shown to provide significant control of LUTS. α1- adrenergic receptor blockers are used as first-line therapy for men to alleviate Benign Prostatic Hyperplasia (BPH) induced urinary symptoms. Similar underlying etiology of LUTS in men and women proposes the utility of α1-adrenergic receptor blockers for female lower urinary tract symptoms (FLUTS). Tamsulosin, the highly uroselective α1-adrenergic receptor blocker, has steadily borne positive results in symptomatic management of FLUTS. Improvement in quality of life has been a vital criteria in the assessment of the efficacy of Tamsulosin. All the reviewed studies substantiate the safety and tolerability of Tamsulosin. Numerous clinical trials of Tamsulosin in women suggest the suitability of Tamsulosin as an appropriate therapeutic option for management of female LUTS.

Keywords


Tamsulosin, Luts/ Fluts, α1-adrenergic Receptors, Bladder, Urethra.

References